Esophageal squamous cell carcinoma (ESCC) is one of the most predominant malignancies worldwide. The 5-year survival rate is still relatively low due to few symptoms presenting with the early disease, diagnosis at middle to late stage, and high risk of recurrence after therapy. Novel protein biomarkers for early detection and treatment of ESCC have the potential to reduce incidence and mortality rates, and significantly prolong the 5-year survival rate. To date, several ESCC biomarkers are being investigated for screening, diagnosis, and treatment to decrease the disease burden. This review summarizes recent developments in candidate protein biomarkers for early diagnosis, predictors for precancerous disease progression, and prognosis of ESCC. Protein biomarkers that enable identification of the different pathologic grades of ESCC will need to be identified. ESCC biomarkers have the potential to improve screening and treatment strategies; multicenter prospective studies with large sample sizes will be required to confirm the usefulness of these candidate biomarkers.
Introduction
Esophageal cancer (EC) is one of the most predominant malignancies. According to the Global Burden of Disease Cancer Collaboration, there were 483,000 new cases of EC in 2015 worldwide, leading to 439,000 deaths, making EC the 11th most prevalent and the sixth deadliest cancer. 1 Over 80% of ECs occur in less developed regions. 1 Although the 5-year survival rate for EC has climbed from 5% to almost 20% during the last 35 years, [1] [2] [3] it is still relatively low due to atypical early symptoms, middleto late-stage diagnosis, and high risk of recurrence after definitive therapy. 4, 5 The two main histologic subtypes of EC are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), which represent approximately 90% of all ECs. 6 EAC is the principal subtype in western countries, whereas ESCC is more common in the Middle East and Asia 6, 7 due to different risk factors in these populations. Gastroesophageal reflux disease is the strongest associated risk factor for EAC, while environmental toxins are the main risk factor for ESCC. [8] [9] [10] [11] ESCC develops gradually from precancerous lesions, and it takes years for precursor lesions to turn into cancer. 9 Precancerous and cancerous lesions of ESCC consist of, in ascending grade: basal cell hyperplasia (BCH), mild dysplasia (mD), moderate dysplasia (MD), and severe dysplasia (SD)/carcinoma in situ (CIS). In addition, some researchers categorize mD and MD as low-grade intraepithelial neoplasia (LGIN), and classify SD and CIS as high-grade intraepithelial neoplasia (HGIN). This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Early diagnosis and treatment of EC significantly increases the 5-year survival rate and decreases mortality. 4, 6 Therefore EC screening campaigns, which use iodine staining followed with endoscopic detection, have been launched in high-risk areas. [12] [13] [14] However, despite the effectiveness of this screening method, no unified standards for the frequency of screening, follow-up, and treatment have been established, contributing to the high prevalence of the disease in some areas. In China, for instance, follow-up only (without treatment) is recommended for mD and MD cases, potentially leading to the undertreatment of patients who tend to progress rapidly. On the other hand, treatment with endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) is strongly recommended for SD/CIS cases, potentially leading to overtreatment, as some patients with SD/CIS can remain cancer-free without treatment. 9 Moreover, because the prognosis of ESCC patients varies considerably among patients of the same age, gender, tumor size, and pathologic grades, individualized medical care should be given to patients based on risk stratification.
Novel methods to stratify ESCC and precancerous lesion patients at high risk from those at low risk are urgently needed to optimize the current screening and treatment strategies. Advances in molecular biology methods have led to the identification of potential biomarkers such as deoxyribonucleic acid (DNA), long noncoding ribonucleic acid (lncRNA), micro-ribonucleic acid (miRNA), and protein for disease assessment.
This concise review focuses on tissue protein biomarkers, rather than blood markers, mutations and genetics, or miRNAs. Blood markers are relatively easy to use and evaluate, although it is hard to verify these markers because they can originate from any part of the body; compared with DNA and RNA, protein is the final functional operator. 15 Tissue protein biomarkers are applicable for diagnosis and prognosis prediction of ESCC and precancerous lesions. We summarize the recent developments in protein biomarkers for the early diagnosis of ESCC, in order to predict the progression of precancerous lesions and the prognosis of ESCC. We used the PubMed database to identify articles for inclusion using the following key search terms "ESCC," "protein," and "biomarkers." Only studies with data on protein biomarkers for ESCC or precancerous lesions in human tissues are included in the review.
Potential protein biomarkers for ESCC and precancerous lesions
Early diagnosis is crucial for early treatment. Analysis of protein expression patterns during the course of the disease has led to the discovery of potential protein biomarkers of ESCC and precancerous lesions that may be useful for the early diagnosis of ESCC.
Potential protein biomarkers for the early diagnosis of ESCC
Proteins that are upregulated in ESCC tissues (as compared to negative controls) have the potential to be valuable biomarkers for the diagnosis of ESCC (Table 1 ). In a study involving 19 ESCC cases (15 adjacent nontransformed squamous epithelium) and nine normal controls, the authors found (using immunochemistry (IHC)) that expression of leukotriene B4 (LTB4R and LTB4R2) and cysteinyl leukotriene receptors (CYSLTR1 and CYSLTR2) was markedly increased in cancer patients compared to normal controls, suggesting a potential role of these two proteins in early steps of esophageal carcinogenesis. 16 Another study in analyzing 96 ESCC cases and adjacent tissues by western blot showed that the expression level of snail and ␤-catenin proteins was significantly higher in ESCC tissues. 17 IHC analysis of ESCC tissues also showed the overexpression of multiple proteins, including A-kinase anchor protein 95 (AKAP95), CyclinE1, and CyclinD1 when compared to adjacent tissues. 18 Another publication reported a significant difference in the expression of mastermind like 1 (MAML1) between tumors and adjacent normal tissues, 19 and a recent study found a positive correlation between sex-determining region Y-box 9 (SOX9) expression and ESCC by IHC. 20 Comparison of 328 ESCC tissues with adjacent normal tissues showed a greater expression of tumor necrosis factor receptor-associated protein 1 (TRAP1) in ESCC tissues (77.1%) compared to the adjacent normal tissue (26.9%). 21 Zinc-binding protein-89 (ZBP-89) was also found to be upregulated in ESCC tissues compared with adjacent normal tissues. 22 Two separate studies found that TFIIB-related factor 2 (BRF2) and claudin-2 were highly specific to ESCC tissues compared with normal tissues. 23, 24 These findings suggest that these proteins could be potentially novel biomarkers for the diagnosis of ESCC. Alternatively, downregulated expression of some proteins could also contribute to ESCC (Table 1) . One study analyzed the expression of 9 Notch signaling-associated proteins in ESCC tissues and found lower levels of Notch1 and Notch2 in cancer foci compared with adjacent tissues. 25 Investigation of tissues samples from 95 ESCC patients and 75 normal controls by IHC using tissue microarray showed that tumor suppressor candidate 3 (TUSC3) was significantly lower in ESCC patients than that in normal controls. 26 These studies suggest that detection of these biomarkers may assist in early diagnosis for ESCC.
Potential protein biomarkers for the early diagnosis of ESCC precancerous lesions
Regularly expressed biomarker. The aforementioned studies summarized protein biomarker candidates that were specifically expressed in ESCC tissues. However, definite conclusions about cause and effect could be drawn if the protein expression was tested in precancerous lesions-prerequisites of ESCC-stratified by lesion severity (grade) ( Table  2) . One study analyzing 77 BCH, 247 LGIN, 51 HGIN, 134 invasive cancer patients, and 80 normal controls from a high-risk area in China found that CEA and CA19-9 might be good candidate markers for diagnosis of dysplasia because their expression rose significantly with increasing grade. The authors further combined the three proteins in a receiver operating characteristic (ROC) analysis and showed that the specificity was 88.8% for normal control with relatively low sensitivity, suggesting that combination of these biomarkers may be useful for identifying high-risk patients with precancerous lesions. 27 Another study reported a statistically significant difference in epidermal growth factor receptor (EGFR) overexpression between lowand high-grade dysplasia and carcinoma among patients with smoking and alcohol consumption history. 28 Analysis of the expression of hepatocyte growth factor (HGF), transforming growth factor ␤1 (TGF-␤1), and ␣-smooth muscle actin (␣-SMA) in ESCC revealed that the expression levels of these proteins rose as lesions became more severe from normal to LGIN, to HGIN, to CIS, to ESCC. 29 One study investigating 143 ESCC, 121 matched normal margin tissues, 96 LGIN, and 53 HGIN specimens showed that overexpression of oral cancer overexpressed 1 (ORAOV1) was apparently more frequent in higher grade lesions. 30 A clinical study carried out in China, wherein the expression of ubiquitin specific protease 9X (USP9X) from normal epithelium adjacent precursor tissues to ESCC was examined, revealed that the expression of USP9X was significantly different between pathologic grades. Interestingly, the strongest staining for USP9X was observed in the basal and lower spinous layers of the tissue where the earliest malignant lesions were located. 31 Evaluation of connective tissue growth factor (CTGF) protein expression in precancerous lesions showed different degree of CTGF protein expression in the normal epithelium, precancerous lesions, and ESCC. 32 Evaluation of the expression of nuclear retinoic retinoid receptors (RAR-␣, RAR-␤, RAR-␥ , RXR-␣), p53, and Ki67 proteins in surgical specimens of normal, mild, SD, and malignant esophageal tissues revealed a robust expression of p53 and Ki67, suggesting that p53 could be a suitable biomarker. 33 Taken together, these studies suggest that some potential biomarkers are correlated with esophageal carcinogenesis and may identify high-risk patients with precancerous lesions.
Because few natural history studies have explored the actual progression of precancerous lesions to ESCC, only a few ESCC protein biomarker candidates indicative of the transition between different grades of precancerous lesions have been identified. One study conducted in high-risk areas in China in which patient tissue samples were analyzed by IHC and followed-up for 4-9 years showed that 80% of precancerous lesions with positive ANO1 expression had progressed while the vast majority (87.8%) of those with negative ANO1 expression did not. These findings were further corroborated in another population-based prospective cohort that found that 75% (3/4) of the positive cases progressed and 25% (1/4) stayed unchanged with SD. 34 Thus, additional research should focus on the transition between precancerous lesions.
Irregularly expressed biomarker. Some protein biomarkers candidates have shown irregular expression patterns (Table 2 ). In a study involving 33 individuals, Annexin II showed a U-shape expression pattern, decreasing with dysplasia progression and reaching its lowest level in CIS lesions, and then increasing in ESCC lesions, which suggested that it could act as a potential biomarker to distinguish esophageal dysplasia. 35 A clinical study that measured Toll-like receptor 9 (TLR9) expression in adjacent normal, dysplastic, and malignant esophageal squamous epithelium, stratified by IHC, revealed that TLR9 expression increased sequentially from superficial layers to the basal layers in normal tissues, while strong expression was observed across full thickness of high-grade dysplasia. The authors further observed that the overall expression of TLR9 was more intensive in dysplastic tissues than in normal epithelium or carcinoma. However, highgrade carcinoma had higher TLR9 expression than low-grade carcinoma. The authors concluded that expression of TLR9, especially in basal sections, could serve as a biomarker for early detection. 36 Recent studies identified a potential role of fascin for the progression from normal epithelium to invasive ESCC by showing that fascin positivity rate was higher in the tumor than normal tissues, although no difference was observed between tumor and dysplasia. The authors further noticed that in normal epithelium, fascin was only apparent in the basal layer, while positive staining was observed from the basal layer to the granular layer in dysplasia, indicating the potential of fascin as a biomarker for positive prediction. 37 These studies suggest that deregulated proteins with no obvious linear patterns (i.e., not trending up or down) could be potential biomarkers, and that focusing on distinct precancerous lesions rather than invasive carcinoma may help uncover new potential protein biomarkers for early detection. Another study reported an atypical expression pattern of SLC39A6 and profilin 2 (PFN2) at different stages; SLC39A6 and PFN2 expression increased in succession from normal to LGIN, to ESCC, and, finally, reached their peak in HGIN lesions, suggesting the potential diagnostic role of SLC39A6 and PFN2 in ESCC. 38, 39 Expression pattern and position of biomarker. Other studies have focused not only on the expression level, but on the expression pattern and position of protein biomarker candidates ( Table 2) . Evaluation of LAMC2 expression in EC lesions showed an atypical pattern described as either continuous, cytoplasmic, diffuse, peripheral, mixed, or negative. 40 All subjects with either normal or dysplastic biopsy results showed the continuous pattern, which was not seen in tumor samples. The most common expression patterns observed in patients with invasive cancer were a peripheral pattern (39%) and a mixed pattern (39%). Follow-up revealed that patients with the diffuse pattern had the shortest survival time (hazard ratio (HR) = 3.54, 95% CI = 1.41-8.87), followed by patients with no expression (negative pattern, HR = 2.69, 95% CI = 1.29-5.63), and patients with a peripheral pattern (HR = 2.30, 95% CI = 1.14-4.63). 40 The authors concluded that LAMC2 could be a promising early detection candidate. Similarly, podoplanin (PDPN) showed an atypical expression pattern by IHC, defined as "complete," "incomplete," or "missing in the basal layer." The study showed that the expression pattern of PDPN in HGIN was incomplete or complete in the basal layer, and that a diagnosis of early infiltration could be made if the expression of PDPN was completely missing, indicating that PDPN could be a potential biomarker to identify the presence of early squamous cell carcinoma. 41 
Summary
The studies cited above demonstrate that specific protein biomarkers may help identify normal, dysplasia, and ESCC patients, and therefore might be useful for ESCC screening and diagnosis for early detection. These cross-sectional studies, however, only provide an association between the biomarkers with certain grades of lesions; they do not fully demonstrate the cause-effect between a biomarker expression pattern and dysplasia. Therefore, additional prospective studies with larger sample sizes are needed to confirm these preliminary findings.
Potential protein biomarkers for the prognosis of ESCC
Surgical resection, chemotherapy, and radiotherapy are standardized treatment protocols for ESCC. However, patients with similar age, gender, tumor size, and pathologic grades undergoing the same treatment may have very different prognosis due to individual variations. Therefore, it is of great importance to find prognosis biomarker candidates that allow stratification of ESCC patients precisely and individually (Table 3) .
A study involving 180 ESCC patients and examining the expression of EGFR, HER2, and c-Met by IHC, showed a significant difference in overall survival between c-Met positive and negative patients (median: 41.9 versus 56.7 months; P = 0.001), but not between EGFR and human epidermal growth factor receptor 2 (HER2) positive and negative patients. 42 Two other studies (conducted in Japan and China) confirmed this finding, that is, that c-Met expression was a good prognostic factor of recurrence-free survival, while EGFR was not. 43, 44 Another study tested EGFR and p53 in 271 ESCC patients by IHC microarray; but no statistically significant better prognosis was associated for either protein 45 . In another study, comparison of EGFR expression in stage IIA ESCC cases showed that the 5-year survival was higher in patients with low EGFR expression than in those with high expression (57.6% versus 37.6%), suggesting that EGFR is an independent marker of prognosis. 46 When further stratifying the EGFR-positive groups by c-Met expression, the authors found that patients with high expression of both EGFR and c-Met had poorer disease-free and overall survival, but not in low c-Met expression group. 47 Even though these studies of EGFR highlight differences in conclusions drawn, EGFR may indeed be a useful protein biomarker when other risk factors are adjusted.
Another study reported a relatively high expression of pituitary tumor transforming gene (PTTG) in 38.0% (41/108) of ESCC patients and further concluded that high levels of PTTG correlated with shorter overall survival, as compared with low levels of PTTG. 48 Increasing evidence suggests that metastasis-associated protein 1 (MTA1) may be a companion diagnostic and prognostic biomarker. MTA1 was overexpressed in ß40% ESCC patients, and its overexpression was associated with lower 5-year survival rate. 49, 50 A study of 85 resected ESCC specimens suggested that hypoxia-inducible factor-1␣ (HIF-1␣) and vascular endothelial growth factor (VEGF) may be candidate markers for poor prognosis, since patients with high HIF-1␣ and VEGF-D had worse survival rates than those with relatively lower expression. 51 Others have evaluated the predictive role of ubiquitin-specific protease 22 (USP22) and found USP22 overexpression in approximately 50% of ESCC patients, which was associated with poorer 5-year survival rates. 52 Glioma-associated oncogene homolog 1 (Gli1), CD44, and SOX9 expression have been linked to worse clinical outcome and poor prognosis of overall survival (P = 0.005) and disease-free survival (P = 0.003) in ESCC. 53 Testing of 328 ESCC and adjacent normal tissues showed that TRAP1-positive patients had higher mortality and shorter overall survival, indicating that TRAP1 might be a protein predictive marker for poor prognosis, 21 High ZBP-89 expression in ESCC patients was correlated with shorter overall survival, compared with low ZBP-89 expression level, 22 and high expression of BRF2 protein was closely associated with tumor progression, angiogenesis, and poor survival of ESCC patients. 23 Evaluation of ORAOV1 expression in 143 ESCC cases showed that the increased expression of ORAOV1 was significantly associated with shorter overall survival. 30 Increased USP9X expression was also significantly correlated with poorer survival rate in ESCC patients. 31 CTGF protein expression was notably correlated to poor survival of ESCC patients after 12 years of follow-up. 32 An atypical expression pattern of SLC39A6 and PFN2 was observed between different lesion stages, showing that high expression of SLC39A6 and PFN2 was associated with shorter overall survival. 38, 39 Low expression of certain proteins has also been associated with poor prognosis. For instance, low TUSC3 expression has been statistically significantly associated with shorter overall survival. 26 This result demonstrates that irregular expression of certain protein biomarkers might be associated with lower 5-year survival rates in patients with ESCC, suggesting their value as prognostic markers.
Conclusions
Many studies have identified potential promising protein biomarkers for the screening, diagnosis, and prognosis of ESCC. However, these studies only offer the first proof-of-concept and have several limitations. First, because these studies were primarily single-center studies (performed in a single hospital), selection bias could occur; thus multicenter studies should be conducted to expand their findings. Second, most clinical studies enrolled a small sample size, thereby limiting the study's power; studies with larger samples sizes should be conducted to provide more definitive conclusions. Third, most studies were cross-sectional or retrospective studies, which are not optimum study designs to test cause and effect; more prospective studies with longer follow-up times should be conducted (in the few studies we discussed that included follow-up, biomarker expression was evaluated at the beginning and at follow-up, but not at different time during oncogenesis). Thus, studies should be designed to thoroughly examine the pattern of biomarker expression longitudinally. Finally, although our concise review focused on tissue protein markers, alternative blood markers, mutations and genetics, or miRNAs may of course be useful biomarkers for diagnosis, prediction of the natural history of disease, or prognosis. Future research should focus on identifying biomarkers that can be found in blood, urine, and/or saliva because their assessment is much less invasive than tissue biomarkers. However, identifying adequate and reliable protein biomarkers for the screening, diagnosis, and prognosis of ESCC, biomarkers that can be easily assessed in blood, will require significantly more research.
